Neurochemistry and Neurophysiology of Methylphenidate
Project Number5R21MH014602-02
Former Number1R21DA014602-01
Contact PI/Project LeaderWATERHOUSE, BARRY DALE
Awardee OrganizationDREXEL UNIVERSITY
Description
Abstract Text
DESCRIPTION (provided by applicant): Attention deficit, hyperactive disorder
(ADHD) is a childhood cognitive disorder characterized by inattentiveness
and/or hyperactivity and impulsiveness. The most effective treatment for ADHD
is chronic low dose administration of amphetamine (AMPH)-like stimulants such
as methylphenidate. All of these agents have prominent effects on monoaminergic
neurotransmission yet little is known regarding the specific mechanism(s)
through which they exert their therapeutic action in ADHD. Almost all of our
information concerning AMPH-like stimulants derives from drug abuse studies
which employ doses far in excess of those used clinically. Furthermore, there
are profound dose and drug-specific differences in AMPH-like stimulant actions
on monoaminergic neurotransmission. The central tenet of the proposal is that
it is inappropriate to postulate therapeutic mechanisms of action for AMPH-like
stimulants on the basis of animal studies of drug abuse. Moreover, a better
understanding of the therapeutic actions of these drugs is needed in order to
develop pharmacological treatments that do not possess the negative properties
of AMPH-like stimulants (e.g. unwanted behavioral side effects, long term
toxicities, abuse potential). The goal of the proposed study is to develop
methodologies for evaluating the effects of therapeutically-relevant doses of
methylphenidate on: 1) catecholaminergic neurotrasmission, 2) the impact of
acute and chronic low dose stimulants on sensory processing, sensory detection
and attention, 3) the receptor mechanism involved in stimulant-induced
alterations in sensory processing, sensory detection and attention, and 4) the
long-term consequences of low dose stimulants on a variety of physiological and
behavioral processes in developing animals. The major techniques to be employed
here include gas chromotography for determining plasma levels of
methylphenidate, microdialysis for determining plasma levels of
methylphenidate, microdialysis for determining catecholamine levels in
specified brain regions, EEG and EMG for identifying behavioral states of
arousal, multi-channel many neuron recording in cerebral cortex, thalamus and
locus coeruleus for characterizing patterns of neural discharge in awake
behaving rats, and computer based analysis of many neuron spike train data.
These studies will fill a significant gap in our understanding of therapeutic
actions of AMPH-like stimulants in ADHD.
No Sub Projects information available for 5R21MH014602-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R21MH014602-02
Patents
No Patents information available for 5R21MH014602-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R21MH014602-02
Clinical Studies
No Clinical Studies information available for 5R21MH014602-02
News and More
Related News Releases
No news release information available for 5R21MH014602-02
History
No Historical information available for 5R21MH014602-02
Similar Projects
No Similar Projects information available for 5R21MH014602-02